Stockscreener 앱 받기
2.10
0.94%
-0.02
시간 외 거래:
2.15
0.05
+2.38%
전일 마감가:
$2.12
열려 있는:
$2.1
하루 거래량:
411.01K
Relative Volume:
0.30
시가총액:
$290.39M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-6.00
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
+0.48%
1개월 성능:
+14.13%
6개월 성능:
+28.83%
1년 성능:
+54.41%
1일 변동 폭
$2.06
$2.165
1주일 범위
$2.06
$2.2299
52주 변동 폭
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.10 | 289.01M | 0 | -45.44M | -42.28M | -0.35 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics CEO acquires $21,100 in common stock - Investing.com Australia
Compass Therapeutics CEO acquires $21,100 in common stock By Investing.com - Investing.com India
Compass Therapeutics CEO Acquires 10,000 Shares - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Brokerages - Defense World
Dimensional Fund Advisors LP Buys New Stake in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Bell Investment Advisors Inc Buys 79 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Dark Forest Capital Management LP Cuts Stock Holdings in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Price T Rowe Associates Inc. MD - Defense World
Ceera Investments LLC Grows Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) is Sound View Wealth Advisors Group LLC’s Largest Position - Defense World
Frontier Asset Management LLC Acquires 1,041 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Rebalance LLC Grows Stake in Apple Inc. (NASDAQ:AAPL) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Voya Investment Management LLC Sells 5,102 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Spotlight On Three Promising Penny Stocks In May 2025 - Yahoo Finance
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Wells Fargo & Company MN Acquires 13,038 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World
Barclays PLC Has $279,000 Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Mariner LLC Purchases New Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus
Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Q1 2025 Financial Results - TipRanks
Compass Therapeutics, Inc. SEC 10-Q Report - TradingView
Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in April - Defense World
Was Compass Therapeutics Inc (CMPX)’s session last reading good? - uspostnews.com
JPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Inc’s Market Journey: Closing Weak at 1.90, Down -2.06 - DWinneX
Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital - Defense World
Compass Therapeutics (CMPX) Unveils Promising Data at AACR Annua - GuruFocus
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com UK
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World
2 Penny stocks to buy in May 2025 - Finbold
It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World
What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com
Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):